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Punctal plugs (PPs) are miniature medical implants that were initially developed for the 19
treatment of dry eyes. Since their introduction in 1975, many PPs made from different materials 20
and designs have been developed. PPs, albeit generally successful, suffer from drawbacks such 21
as epiphora and suppurative canaliculitis. To overcome these issues intelligent designs of PPs 22
were proposed (e.g. SmartPLUG and Form Fit). PPs are also gaining interest among 23
pharmaceutical scientists for sustaining drug delivery to the eye. This review aims to provide an 24
overview of PPs for dry eye treatment and drug delivery to treat a range of ocular diseases. It 25
also discusses current challenges in using PPs for ocular diseases.26
27
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27
Introduction28
Ocular diseases range from a simple inflammation (e.g. conjunctivitis) to serious loss of vision 29
(e.g. age-related macular degeneration). Depending upon the origin of ocular disease, drug 30
delivery can be achieved through different routes such as topical, transscleral and intravitreal. 31
Drug delivery to the eye can also be classified anatomically into two segments, namely anterior 32
and posterior segment drug delivery. Ocular diseases if left untreated can lead to partial or 33
complete loss of vision. For example, anterior segment diseases that can cause serious vision 34
impairment include eyelid anomalies (e.g. Sjögren’s disease, injuries, radiation or mucin 35
deficiency), glaucoma, bacterial keratitis, uveitis, herpes simplex keratitis, refractive surgery, 36
blepharitis and dry eye syndrome (DES) or keratoconjunctivitis. Similarly, chronic posterior 37
segment diseases such as diabetic retinopathy, diabetic macular edema, age-related macular 38
degeneration and other chorioretinal diseases can lead to vision impairment or blindness if left 39
untreated.40
Development of therapeutics for treatment of ocular diseases is a challenging task for 41
pharmaceutical formulators and scientists. This is because of the sensitivity of the ocular tissues 42
and the presence of various physicochemical and biological barriers for drug delivery. Of the 43
different routes of drug delivery, topical administration (e.g. eye drops) remains the most widely 44
accepted and preferred route of administration because of its ease of access and patient 45
compliance. However, the bioavailability of topically administered drugs is compromised by 46
factors such as blinking, tear production and barrier function of the cornea, which allows only 47
1% or less of the total dose to be administered. Thus, drug delivery modalities that can increase 48
drug bioavailability (extending the duration of release, decreasing the amount of drug delivered, 49
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minimizing systemic exposure and improving patient compliance and adherence) will certainly 50
offer many advantages over conventional eye drops [1,2]. Some of these approaches include use 51
of mucoadhesives, prodrugs, nanospheres, liposomes, inclusion of permeability enhancers, 52
implants and punctal or punctum plugs (PPs). This review will focus on the ocular applications 53
of PPs. First, it reviews the use of PPs as a medical device initially developed to physically block 54
the puncta of the eye to treat DES. Second, it reviews the application of PPs for drug delivery to 55
the anterior segment of the eye.56
Dry eye syndrome57
DES or keratoconjunctivitis sicca is one of the most common ocular disorders frequently 58
discussed in the office of eye-care specialists. In the USA, the average annual cost of managing a 59
patient with DES was US$783 (or US$3.3 billion in total) in 2011. Furthermore, from a societal 60
perspective it was estimated that DES costs US$11 302 per patient (or US$55.4 billion overall) 61
in the USA [3]. The symptoms of DES often include dryness, photophobia, burning and stinging, 62
itching, eye fatigue, pain and redness (hyperemia) [4,5]. DES is estimated to affect between 14% 63
and 33% of the population worldwide, henceforth it is a significant public health concern [6]. 64
The pathophysiology of DES usually includes poor production of the ocular tear film and 65
evaporation of tears. In addition, causes of DES include formation of unstable tear film 66
associated with abnormality of the lipid, protein and mucin profiles and inflammation of the 67
ocular surface and tear producing glands [4]. Better understanding of complex pathophysiology 68
and underlying mechanisms of DES has led to development of numerous pharmacological and 69
nonpharmacological treatment options for DES. However, a detailed discussion on treatment of 70
DES is out of the scope of this review, readers can refer to reviews in the literature [7–11].71
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Treatment of DES73
There is no cure for DES but there are treatment strategies to mitigate symptoms. For example, 74
the National Health Service in the UK provides a range of choices for treating DES. The primary75
nonpharmacological treatment of DES involves the use of tear substitutes, also called artificial 76
tears or lubricant treatment, that consist of a range of drops, gels and ointments. Tear substitutes 77
improve lubrication and enhance humidity at the ocular surface. Tear substitutes usually contain 78
additives such as polymers including carboxy methyl cellulose, polyvinyl alcohol, 79
hydroxypropyl methylcellulose or carbopol 940, which act as lubricants, buffers to maintain the 80
pH of natural human tears (pH 7.4) and electrolytes to m intain osmolarity [12–15]. However, 81
use of artificial tears will provide short-term symptomatic relief but will not solve the underlying 82
problem with long-term DES: inflammation. In such cases, anti-inflammatory treatments are 83
prescribed such as steroid eye drops and ointments, oral tetracyclines and cyclosporine eye 84
drops. Another alternative in treating DES is the use of PPs, which is discussed in greater detail 85
in the sections below.86
PPs for DES and other ocular applications87
Punctal or tear duct occlusion involves temporary blocking of the puncta using PPs or permanent88
blocking by cauterizing [16]. Blocking the punctum results in increased tear fluid accumulation89
and thus keeps the eye moist. PPs cause occlusion of tear drainage by blocking the tears through 90
the canaliculi, which connects the eye to the nose (Figure 1). Because of their ability in tear 91
preservation, PPs are indicated in certain cases of laser in situ keratomileusis and contact lens 92
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intolerance [17]. It was also reported that insertion of PPs improves tear film stability, tear 93
osmolarity and functional visual acuity in dry eye patients [18,19].94
Unlike temporary or short-term relief provided by the artificial tears, PPs can provide long-term 95
relief owing to enhanced tear retention and, therefore, enhanced patience compliance. Although 96
developed initially to physically block the puncta, PPs have also been engineered for controlled 97
drug delivery enabling treatment of DES and other anterior ocular conditions [20]. Foulds 98
introduced the first PPs in 1961, which involved dissolvable gelatin implants to block the puncta 99
temporarily [21]. Recently, Qiu et al. reported a clinical study that compared efficacy of PPs 100
versus artificial tears for treating primary Sjögren’s syndrome with keratoconjunctivitis sicca. 101
The results indicated that punctal plugs were significantly better at improving dry eye symptoms 102
in comparison with artificial tears [22]. However, in 1975, Freemen developed the modern PP 103
design that was a dumbbell-shaped plug made of silicone. To date, this concept of plug designs 104
remains the prototype and, recently, a number of designs were developed either to enhance plug105
retention or to provide drug delivery or both [23].106
PPs are either semi-permanent or temporary depending on the material used for their preparation. 107
Semi-permanent PPs are made using silicone, Teflon®, hydroxyethyl methacrylate (HEMA), 108
polycaprolactone (PCL) or polydioxanone; and temporary PPs are made from animal collagen. 109
Semi-permanent PPs either dislodge spontaneously or should be removed by a physician. Plugs 110
fabricated using collagen dissolve within four to seven days; or certain polymer-based plugs last 111
for variable periods of time ranging from three days to six months [13,24,25]. Table 1 lists a few 112
examples of currently marketed PPs that have been fabricated from different materials. For an 113
extensive list readers are requested to refer to [26]. The plugs are either preloaded onto an 114
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applicator or applicator/inserters are provided to aid application into the eye. To facilitate 115
insertion of PPs across the punctum local anesthesia and/or a lubricant is applied.116
Although insertion of PPs is an effective therapy for treatment of DES many complications are 117
associated with their use. Some of the recognized complications of PPs include epiphora 118
(overflow of tears), suppurative canaliculitis (infection of the lacrimal gland causing surface 119
abnormalities), punctal ring rupture or spontaneous dislodging and abrasion of the corneal and 120
conjunctival surface [29-32]. Therefore, the criteria for designing the PP is dependent upon many 121
factors such as the purpose of application (tear retention or drug delivery), required length of 122
retention (short-term or long-term), patient compliance and/or commercial value. Interesting 123
examples of various PP designs were proposed by Eagle Vision, as shown in Figure 2. Here, 124
assorted PP designs have been engineered from silicone. Similarly, to enhance retention of PPs125
in the puncta, SmartPLUG (Medenium, CA, USA) was developed. SmartPLUG is made 126
from biocompatible hydrophobic thermosensitive copolymer compositions of poly 127
(stearylmethacrylate) (SMA) with methylmethacrylate (MMA). These polymeric materials are 128
blended to form a composition, which has a glass transition temperature (Tg) or melting 129
temperature (Tm) at or below human body temperature (37°C). SmartPLUG is a slender rod 130
that is solid at room temperature with a diameter of 0.4 mm and length of 9 mm prior to 131
insertion. After insertion into the ocular channel the diameter increases up to 1 mm and its length 132
decreases to 2 mm. This expansion results in the adaptation and subsequent fixation of 133
SmartPLUG to the size and shape of a patient’s punctum or canaliculum [18,33]. In another134
attempt to improve patient tolerability of PPs, Form Fit intracanalicular plugs were developed. 135
Form Fit plugs are made of a hydrogel containing hydrophilic and hydrophobic domains. The 136
hydrogel is prepared by copolymerizing a hydrophilic monomer such as water-soluble N-vinyl 137
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carbazole with a hydrophobic monomer N-vinylpyrolidone derivative. The hydrogel expands 138
into a soft, pliable, gelatinous material after coming into contact with tear film. Form Fit plugs 139
absorb tear fluid and expand 20-times in volume after approximately 10 min of insertion, filling 140
and conforming to the size and shape of the vertical canaliculus [34,35].141
PPs as controlled drug delivery implants142
Since the introduction of PPs for the treatment of dry eyes by Freeman in 1975 [23], many 143
different types of PPs have been developed and are in widespread use. PPs have recently been144
investigated for the controlled delivery of drugs to the tear fluid of the eye and the nasolacrimal 145
duct. PPs can offer numerous advantages over topical drug delivery such as reduction in loss of 146
drug and/or formulation owing to tear formation, reduction in lacrimal drainage of drug, ability 147
to achieve controlled drug delivery, patient compliance and possibly reduced costs.148
Drug loading and drug release from PPs can be achieved in different ways (Figure 3). For 149
example, the drug can be loaded within the core of the PPs within the surrounding impermeable 150
layer: the drug essentially diffuses out from the cross-section which is in contact with tears 151
(Figure 3). Alternatively, pre-formed plugs can be coated with drug solution; however, 152
considering the dimensions of the PP, the quantity of drug coating might be limited owing to the 153
small surface area. Nevertheless, drug-releasing PPs not only improve the ability of drug to avoid 154
rapid clearance from the ocular surface but also release the drug into the ocular cavity for an 155
extended period of time.156
The latanoprost PP delivery system (L-PPDS) was recently developed for controlled elution of 157
latanoprost for the treatment of open-angle glaucoma (OAG) and ocular hypertension (OH). The 158
L-PPDS comprises a reservoir containing a polymeric blend of latanoprost which is housed in a 159
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PP and this reservoir has an opening through which drug will be released after coming into 160
contact with tear film. A 44 µg L-PPDS has one-third the amount of drug in latanoprost eye 161
drops given continuously over three months [36]. L-PPDS recently completed a Phase II clinical 162
trial evaluating the safety, efficacy and dosing for the treatment of OAG and OH patients. 163
Results have indicated that L-PPDS showed positive efficacy trends with statistically and 164
clinically significant findings [37]. The PP device used in L-PPDS is also being investigated as a 165
platform to deliver the anti-allergy drug olopatadine for treatment of patients with allergic 166
conjunctivitis. Interim results from a Phase II proof-of-concept trial have shown that olopatadine 167
PP drug delivery system (O-PPDS) did not show significant difference in efficacy when 168
compared with placebo-PPDS with respect to reduction in the signs and symptoms of allergic 169
conjunctivitis [38]. The reason for the lack of efficacy of O-PPDS was reported to be due to the 170
environmental exposure chamber (EEC) model utilized in the trial not being sensitive enough to 171
demonstrate the potential benefit of the O-PPDS [39]. Latanoprost was initially loaded into 172
PLGA microspheres and incorporated into hydrogel-based PPs. The in vitro release profile of 173
latanoprost from PPs has shown that drug is released up to 90 days and the release profile is 174
dependent upon PLGA crosslinking and its chemical nature. Moreover, the PPs did not show any 175
initial burst release of latanoprost in any of the formulations [40].176
Gupta and Chauhan reported a cyclosporine-A-releasing PP delivery system for treating dry 177
eyes. These PPs consisted of a cylindrical hydroxyl ethyl methacrylate (HEMA) cross-linked 178
with an ethyeneglycol dimethacrylate (EGDMA) core containing cyclosporine microparticles 179
covered by an impermeable silicone shell. Cyclosporine A was released for three months at a 180
zero-order rate of about 3 µg/day [41]. The in vitro release studies have shown that PPs with 181
drug loading of 20% released drug at a rate of 3.5 µg/day for a period of one month without any 182
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initial burst release. The release was reasonably zero-order for the first ten days for these PPs. 183
However, the release was decreased when crosslinking of HEMA with EGDMA was increased 184
and the release profile was non-zero-order for the entire duration. An ocular pharmacokinetic 185
model was developed by performing a mass balance on the drug released into the ocular tear 186
film. This model predicted that the in vivo release of cyclosporine A from PPs is approximately 187
1.5 µg/day with an ocular bioavailability of 64% [41].188
In another study, PPs loaded with antibiotic moxifloxacin (MOX) were developed (Ocular 189
Therapeutix, MA, USA) for extended delivery of the drug for the treatment of bacterial 190
conjunctivitis. This PP comprises a dried polyethylene glycol hydrogel rod that is embedded with 191
MOX-encapsulated microspheres that release drug for ten days. The PPs released MOX at a 192
concentration greater than the target concentration of 250 ng/ml, which is the target minimum 193
inhibitory concentration (MIC90) up to ten days as calculated from mean tear fluid 194
concentrations. However, the concentrations of MOX were below detectable limits at day 20 and 195
day 30. A clinical study has reported that MOX-PPs were well tolerated, released and maintained196
MOX tear fluid concentrations at therapeutic levels above the MIC90 values for seven days for 197
common susceptible conjunctivitis pathogens [42]. These studies clearly indicate the potential of 198
PPs for controlled delivery of drugs to the eye.199
Chee assessed the safety and feasibility of a MOX-loaded PP in cataract patients. After cataract 200
surgery, MOX was inserted into the punctum and follow-up assessments were continued for 30 201
days. The study was conducted in two groups and each group consisted of ten cataract patients. It 202
was observed that the retention of MP in the punctum was 95% to day ten in 19 patients and all 203
plugs were absent at day 30 for both studies. MP was delivered and maintained drug 204
concentration in the tear fluid at therapeutic levels (above 250 ng/ml) for seven days and 205
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exhibited a favorable safety and tolerability profile. It was concluded that it might be a viable 206
alternative to topical antibiotic drops for the treatment of bacterial conjunctivitis [42]. Ocular 207
Therapeutix conducted a single-site, single-armed, single-dose study using a pool of ten patients 208
and implanted a novel sustained drug delivery MOX-PP immediately following cataract surgery. 209
The patients were evaluated over a ten-day period. The MOX-PP achieved 100% retention in all 210
ten patients and drug levels were maintained well above MIC90 (2000 and 3000 ng/ml). Hence, 211
the results demonstrated the sustained levels of MOX throughout the ten-day treatment period. 212
Furthermore, there were no adverse events and ocular complaints outside the normal post-213
cataract symptoms [43].214
Overall, drug-loaded PPs are potential devices for improved delivery of drugs to the ocular 215
cavity. Drugs that have poor ocular bioavailability can be loaded into PPs with a desired release 216
rate with significantly enhanced bioavailability. The polymeric composition of PPs can be 217
modified to obtain the desired release rate of a drug based on requirements of the disease 218
condition. Furthermore, a few studies have also reported combination of topical eye drops with 219
PPs that has resulted in enhanced drug delivery to the eye [44]. This clearly indicates the 220
overarching advantages of using PPs over conventional eye drop preparations that need frequent 221
dosing.222
Current challenges of using PPs223
Although PPs have demonstrated their advantages as drug delivery vehicles for the treatment of 224
DES, their use is associated with complications including mechanical conjunctivitis, plug 225
extrusion, spontaneous distal migration, epiphora, corneal abrasion, suppurative canaliculitis, 226
dacryocystitis and distal lachrymal system blockage [26,29]. In a study with silicone plugs (FCI 227
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Ophthalmics) spontaneous loss happened in 14.7% after three months, 27.3% after one year and 228
36.8% after two years [45]. In another study involving the modified Freeman ‘tapered-shaft’ 229
plug (Eagle Vision) and SoftPlug (OASIS Medical), it was reported that 47% spontaneous loss 230
occurred at six months with the majority being lost in the initial three months of the study [24]. 231
The reasons for PP extrusion were attributed to mucosal dissection by the plug edges leading to 232
necrosed tissue and pyogenic granuloma formation [46]. Migration of the PP into the lacrimal 233
drainage system is another major complication that could require surgi al intervention for 234
removal of the plug. The migrated plug can cause canaliculitis and dacryocystitis owing to a 235
local inflammatory reaction triggered by allergens and debris attracted by the negatively charged 236
surface of the silicone [47]. Complications such as punctal and proximal canalicular stenoses 237
after plug extrusion or migration were reported in a frequency of 25.7% during a period of 32 238
months [46]. In a separate study, canalicular stenosis occurred in 14.3% after three months, 239
26.9% after one year and 34.2% after two years [45].240
Epiphora, which is the production of exc ssive tears, is another complication associated with use 241
of PPs. It was reported that mild epiphora occurs in up to 36% patients. Although most patients242
tolerate the epiphora, up to 5% request removal of the plugs [48]. Pyogenic granuloma leading to 243
plug extrusion was reported to occur for the silicone plug and SmartPLUG. In a study 244
conducted in 404 patients with silicone PPs, pyogenic granuloma resulted in extrusion of 4.2% of 245
all plugs inserted after a median time of 141 days. Furthermore, large plug size was considered to 246
be the major risk factor leading to granuloma formation [47]. In a retrospective study of247
SmartPLUG with 28 patients, 64.3% had canaliculitis, dacryocystitis or conjunctivitis [49]. A 248
more recent study with a total of 1026 patients receiving SmartPLUG was reported by Fezza et 249
al. [50]. According to the published results, the average time to develop canaliculitis after 250
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SmartPLUG insertion was 2.7 years with the lower left lid being the most common site, 251
followed by the right lower, right upper and left upper lids. The study reported a total of 61 cases 252
of SmartPLUG-induced canaliculitis representing 6.0% canaliculitis rate [50]. Overall, based 253
on results from clinical studies, the reasons for complications relating to PPs can be attributed to 254
effects of design, sizing and method of insertion.255
Concluding remarks256
PPs offer a safe and effective treatment for the patients with aqueous deficient dry eye and/or for 257
sustaining drug delivery to other conditions. The patients often benefit with symptomatic relief 258
and clinically measurable improvements. Therefore, this therapeutic approach can improve the 259
quality of life of many patients with severe conditions associated with the anterior segment of the 260
eye (e.g. dry eye or other infections). Careful selection of the optimal plug size and continuous 261
follow-up would be beneficial to maximize the success rate of the treatment. Based on the 262
progress achieved so far and the number of therapies in the pipeline, the future of PP-based dry 263
eye therapy or drug delivery seems optimistic. However, the experience and knowledge gained 264
from previous clinical studies will be helpful in overcoming many of the current drawbacks, so 265
that newer and effective PPs can be designed for simply blocking the puncta (for DES) and/or 266
sustaining drug delivery to the anterior segment of the eye. It is too early to comment on PP267
application for posterior drug delivery. However, following successful demonstration of anterior 268
drug delivery, technologies such as specialized nanoparticle loaded PPs can be sought for long-269
acting posterior drug delivery.270
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Figure legends372
Figure 1. Schematic illustration of punctum location (inset) and placement of punctual plugs 373
(PPs) in the punctum of the eye. 374
Figure 2. Schematic representation of assorted designs of silicone-based punctual plugs (PPs), 375
where each design has been claimed to provide a unique advantage to the dry eye syndrome 376
(DES) patients. (a) PLUG1 (CE marked) is a unique dual-lobed design that allows it to fit a 377
wide range of punctum sizes. (b) SUPEREAGLE® (CE marked) design uses soft and low 378
durometer silicone that claims to provide “super patient comfort”. The tapered shaft and pivoting 379
wide-flex nose design allows “super retention”, available in three different sizes. (c)380
SUPERFLEX® is claimed to be a better fit design that is easier for insertion and provides greater 381
patient comfort. This device is available in multiple sizes. (d) EAGLE FLEXPLUG™ is the only 382
tapered shaft™ PP with contouring traction ribs. This design is claimed to provide the ultimate in 383
flexibility, fixation and patient comfort. (e) EAGLEPLUG® is an easy to insert and remove 384
design [51].385
Figure 3. Schematic illustration of a punctal plug delivery device.386
387
Table 1. List of different types of PPs that were fabricated in different shapes and from 388
different biodegradable and nonbiodegradable polymeric materials389
390
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Highlights:390
 Punctal plugs (PPs) are miniature medical devices that are used to block puncta to treat dry eye syndrome391
 PPs are currently been investigated as sustained-release drug delivery devices392
 Sustained-release PPs can be used to treat a range of anterior segment eye diseases393
 Drug-loaded PPs showed improved ocular bioavailability when compared to eye drops394
 PPs with nanoparticles can achieve drug delivery to the posterior segment of the eye395
396
397
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Table 1. List of different types of PPs that were fabricated in different shapes and from different 
biodegradable and non-biodegradable polymeric materials. 
Brand Design Dimensions Composition Application Ref
SOFT PLUG
Collagen 
Rod-shaped 2 x 0.2 mm, 2 x 
0.3 mm and 2 x 
0.4 mm
Collagen. 
Absorbable 
within 2-5 days
For short-term, 
diagnostic, and 
postsurgical occlusion. 
[27]
SOFT PLUG 
Silicone Plugs 
Pointed nose to allow 
easy insertion with 
large anchor with 
wide shelf firmly 
secures plug making 
dislocation. 
0.4, 0.5 and 0.7 
mm with 0.8 
mm diameter
Medical grade 
Silicone
Control of tear drainage 
through the canaliculus
[27]
FORM Fit Semi-rigid rod 0.3 x 2.5 mm 
0.3 mm one size 
fits all
Polyvinyl 
pyrrolidinone 
(PVP) based
Hydrogel. 
Hydrates over a 10 min 
period. Upon contact 
with
Tear fluid, the plug will 
slowly swell to approx. 
3 times its initial size to 
completely fill the 
vertical canalicular 
cavity.
[27]
SOFT PLUG 
Extended 
Duration Plugs 
[http://oasismed
ical.com/dry-
eye-
products.html]
Rod-shaped design 2 x 0.2 mm, 2 x 
0.3 mm, 2 x 0.4 
mm, & 2 x 0.5 
mm
Absorbable 
copolymer of 
glycolic acid 
and trimethylene 
carbonate and 
dyed with D&C 
Green Number 
6.
Block tear drainage. 
Less than 3 months
[27]
Snug Plugs™ Preloaded in a 
stretched position, 
returning to their 
natural shape when 
released in the 
punctum
NA Medical grade 
silicone
Dry eye [28]
Ready-Set" Collarette plugs 0.4 to 1.0 mm 
diameter
Medical grade 
silicone
Dry eye [28]
